Clinicotherapeutic Potential of Leptin in Alzheimer’s Disease and Parkinson’s Disease
Author(s) -
Soumyabrata Munshi,
Vineet Kumar Khemka,
Kalpita Banerjee,
Sasanka Chakrabarti
Publication year - 2014
Publication title -
asian journal of neuroscience
Language(s) - English
Resource type - Journals
ISSN - 2314-7482
DOI - 10.1155/2014/181325
Subject(s) - leptin , disease , neuroprotection , medicine , clinical trial , parkinson's disease , hormone , population , neuroscience , bioinformatics , psychology , obesity , biology , environmental health
Chronic neurodegenerative diseases are a group of devastating neurological disorders that result in significant morbidity and mortality in the elderly population worldwide. Recent researches have shown some interesting associations of the classical antiobesity hormone leptin with two most important neurodegenerative diseases—Alzheimer’s disease (AD) and Parkinson’s disease (PD). Although several clinical studies have found the procognitive and memory-enhancing role of this peptide hormone in leptin-deficient patients, surprisingly it has not been used in any clinical trials involving patients with developing or full-blown neurodegenerative conditions. This review article is an attempt to bring together the existing information about the clinical associations of leptin with AD and PD. It starts with the basic understanding of leptin action in the brain and its derangements in these diseases and eventually discusses the potential of this hormone as a neuroprotective agent in clinical scenario
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom